Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2026 11:00 ET | Source: Hopewell Therapeutics

Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics

Transaction is Hopewell’s first commercial license of proprietary lipid nanoparticles (LNPs)Hopewell’s LNPs are the preferred delivery solution for the cancer vaccine technology that Foxcroft licensed...